Exact Sciences CORP 8-K Filing
Ticker: EXAS · Form: 8-K · Filed: Nov 20, 2025 · CIK: 1124140
| Field | Detail |
|---|---|
| Company | Exact Sciences CORP (EXAS) |
| Form Type | 8-K |
| Filed Date | Nov 20, 2025 |
| Pages | 9 |
| Reading Time | 11 min |
| Key Dollar Amounts | $0.01, $105.00, $628,694,446 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Exact Sciences CORP (ticker: EXAS) to the SEC on Nov 20, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.01 (ange on which registered Common Stock, $0.01 par value per share EXAS The Nasdaq); $105.00 (ereafter represent the right to receive $105.00 in cash, without interest (the " Per Sh); $628,694,446 (d to pay to Parent a termination fee of $628,694,446. The foregoing description of the Mer).
How long is this filing?
Exact Sciences CORP's 8-K filing is 9 pages with approximately 2,664 words. Estimated reading time is 11 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 2,664 words · 11 min read · ~9 pages · Grade level 18.5 · Accepted 2025-11-20 08:02:02
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value per share EXAS The Nasdaq
- $105.00 — ereafter represent the right to receive $105.00 in cash, without interest (the " Per Sh
- $628,694,446 — d to pay to Parent a termination fee of $628,694,446. The foregoing description of the Mer
Filing Documents
- d38144d8k.htm (8-K) — 44KB
- d38144dex21.htm (EX-2.1) — 549KB
- d38144dex991.htm (EX-99.1) — 32KB
- g38144g1120130647329.jpg (GRAPHIC) — 4KB
- g38144g1120130647454.jpg (GRAPHIC) — 3KB
- 0001193125-25-288896.txt ( ) — 888KB
- exas-20251119.xsd (EX-101.SCH) — 3KB
- exas-20251119_lab.xml (EX-101.LAB) — 17KB
- exas-20251119_pre.xml (EX-101.PRE) — 11KB
- d38144d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description Exhibit 2.1 Agreement and Plan of Merger, dated as of November 19, 2025, by and among Abbott Laboratories, Badger Merger Sub I, Inc. and Exact Sciences Corporation. Exhibit 99.1 Press release, dated November 20, 2025. Exhibit 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document) Important Information and Where to Find It In connection with the proposed transaction, Exact will file with the SEC a proxy statement, the definitive version of which will be sent or provided to Exacts stockholders. Exact may also file other documents with the SEC regarding the proposed transaction. This communication is not a substitute for the proxy statement or any other document that may be filed by Exact with the SEC. INVESTORS AND SECURITY HOLDERS OF EXACT ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY, BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain the proxy statement (when it is available) and other documents that are filed with the SEC by Exact free of charge from the SEC's website at https://www.sec.gov or through the investor relations section of Exact's website at https://www.exactsciences.com. Participants in the Solicitation Exact and its directors and certain of its executive officers and other employees may be deemed to be participants in the solicitation of proxies from Exact's stockholders in connection with the proposed transaction. Information about the directors and executive officers of Exact and their ownership of Exact common shares is contained in the definitive proxy statement for Exact's 2025 annual meeting of shareholders, which was filed with the SEC on April 29, 2025, including under the headings "Information Concerning Directors and Nominees for Director," "Information Con
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 20, 2025 Exact Sciences Corporation By: /s/ Aaron Bloomer Aaron Bloomer Executive Vice President and Chief Financial Officer